This post was originally published on this site
(Reuters) – Johnson & Johnson (NYSE:JNJ)’s Janssen unit has sued Amgen Inc (NASDAQ:AMGN) over its plan to market an ulcerative colitis drug similar to J&J’s Stelara, saying it would infringe two patents.
Stelara is a major seller for J&J, bringing the company nearly $2.5 billion in the third quarter of 2022.
